The boom in GLP-1 weight-loss drugs is boosting demand for protein supplements and driving a rally in the stock of Glanbia Plc, a maker of nutrition products popular with gym enthusiasts and athletes.

Carley is a writer, editor and social media professional. Before starting at Forbes Health, she wrote for Sleepopolis and interned at PBS and Nickelodeon. She's a certified sleep science coach and ...

The arrival of summer means beach season is calling for many, which may lead some to chase the perfect swimsuit physique. A 2025 Gallup poll showed that 52% of Americans want to lose weight but that ...

The story of GLP-1 drugs keeps getting bigger. First they transformed the treatment of diabetes. Then they upended the science — and culture — of weight loss. Now a growing body of research is raising ...

You’ve probably heard of Ozempic or Wegovy. These are the injectable drugs that have become household names for weight loss and diabetes. Now, researchers are investigating whether these medications ...

Eli Lilly this month unveiled startling new data that showed an experimental weight-loss drug caused people with obesity to shed, on average, 28 percent of their body weight — a substantial step up in ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Lung cancer is among the conditions that may be affected. GLP-1 medications such as Wegovy, ...

GLP-1 drugs may be linked to a lower risk of cancer progression, according to new research that will be presented next week at the American Society of Clinical Oncology’s annual meeting. Limited time: ...

The use of GLP-1 medications for weight loss continues to rise. One drawback associated with GLP-1 medications is that weight loss not only includes fat loss, but muscle loss as well. A new study ...

A quick stroll through any grocery store reveals scores of products courting GLP-1 users with promises of high protein, increased fiber and low sugar, but the acronym GLP-1 is still rarely explicitly ...

Researchers at Toronto's Sinai Health have found that semaglutide—the active ingredient in popular weight loss drugs that mimic the gut hormone GLP-1—acts directly on a subset of liver cells to ...